Week in Review: Xynomic Signs $502 Million Deal for Boehringer's RAF Inhibitor

Deals and Financings Xynomic Pharma, a US-Shanghai novel drug developer, agreed to pay up to $502 million for global rights to a Boehringer Ingelheim 2nd-gen RAF inhibitor; Japan 's Sumitomo Dainippon Pharma announced a $300 million deal to develop Poxel's novel type 2 diabetes drug in Japan , China and other Asian countries; Annoroad, a Beijing genetics services company, raised $100 million in a Series C financing, led by SAIF Partners; Two China companies--Tonghua Golden-Horse Pharma and Golden Meditech--will submit bids in the $765 million auction for Australia 's I-MED Radiology; Shanghai Fosun Pharma will pay up to $98 million to buy the 69% of Henlix Biotech, a Taiwan-US biosimilar company, it doesn't already own; Shanghai Fosun Pharma will pay $73 million to acquire Tridem Pharma, a French drug distributor with operations in 21 French-speaking African countries; Hong Kong 's iPharma in-licensed global rights from Boehringer Ingelheim for a focal adhesion kinase inhibitor aimed at solid tumor cancers; Sinotau Pharma of Beijing signed an MOU with Navidea Biopharma to transfer rights for Navidea's beta-amyloid imaging agent to a Sinotau JV subsidiary; Guangzhou Pharma may partner with Teva Pharma, the world's largest generic drugmaker, to form a JV that would bring Teva's generics to China ; CRO/CMO News WuXi Biologics opened a joint laboratory in Shanghai with Pall Corporation to improve mAb processing and lower mAb manufacturing cost to $5/g; Trials and Approvals Eye Tech Care SA, a French medical device company, received CFDA approval to begin marketing its ultrasound glaucoma treatment product in China .  Stock Symbols: (TSE: 4506) (Euronext: POXEL) (SHZ: 000766) (HK: 0801) (SHA: 600196; HK: 2196) (NYSE: NAVB) (NYSE: TEVA) (HK: 2269) Share this with colleagues: // //